Heino von Prondzynski, Chairman
Mr. Heino von Prondzynski (*1949, Swiss/German) studied mathematics, geography, and history at the Westfälische Wilhelms University, Münster, Germany.
After graduation, Mr. von Prondzynski joined Bayer AG, where he held several positions within the company. Among other career accomplishments, Mr. von Prondzynski served as CEO of the diagnostics division of F. Hoffmann-La Roche Ltd., Basel, Switzerland and a member of the corporate executive committee of Roche. Currently, he is an independent consultant. Mr. von Prondzynski is an expert and business leader in the field of molecular diagnostics with an extensive professional network.
Mr. von Prondzynski was a Supervisory Board member of Epigenomics AG from May 2007 to March 2010, and has been a Supervisory Board member again since May 2012 (Chairman). The current term ends in 2021. He is an independent member (within the meaning of the German Corporate Governance Code).
Mr. von Prondzynski is a member of comparable boards with supervisory function of the following companies: HTL-STREFA S.A., Warsaw, Poland (vice-chairman); Koninklijke Philips N.V. (Royal Philips Electronics), Eindhoven, The Netherlands; Quotient Ltd., Jersey, United Kingdom.
Mr. Heino von Prondzynski was a member of comparable boards with supervisory function of the following companies: Tecan AG, Männedorf, Switzerland; Hospira, Inc., Illinois, U.S.A.; Qiagen N.V., Hilden, Germany; I-MED Network, Sydney, Australia.